Maiwald is partner of the 3rd Annual Life Science Strategy Summit on IP & Exclusivity from October 8-10 in Munich

We are delighted to support the third annual Life Science Strategy Summit on IP & Exclusivity as a Platinum Partner!

This industry-leading life science legal event brings together the leading pharma and biotech experts for three days of practical discussion on the protection of pharmaceuticals based on patent and regulatory exclusivity.

This year’s highlights include:

(1) An overview of recent SPC waiver decisions and their implications for your generic and innovative medicines exclusivity strategy.
(2) Intersections between regulatory and IP law with industry-led sessions on: clinical trials, data exclusivity, a review of case law on Tecfidera and the pharmaceutical strategy for Europe.
(3) Patentability requirements in the life sciences industry with panel discussions on patent quality, G2/21, enablement and the PTAB.
(4) Discussing the impact of the UPC on your life sciences strategy with an industry-led session and a panel of judges.

In addition, two of our colleagues will be there as speakers:

Dr. Marco Stief on 8 October at 11:10 on ‘The Manufacturing Waiver: Is the System Functioning Well and What is the Latest European Case Law?’ and Dr. Eva Ehlich on 9 October at 15:15 on ‘Transcontinental Update on Regulatory and IP Strategies Surrounding Clinical Trials’.